SPY322.64-7.66 -2.32%
DIA267.58-5.23 -1.92%
IXIC10,632.99-330.65 -3.02%

UPDATE: Cantor Fitzgerald Maintains Neutral On Incyte, Lowers Target To $65 Notes 'We are cautious on chronic opportunity of itacitinib, though acute and chronic do have some pathological differences'

Benzinga · 01/03/2020 15:46